| Robert Schweiss, | |
|
3600 Nw Samaritan Dr, Corvallis, OR 97330 | |
| (541) 768-5111 | |
| Not Available |
| Full Name | Robert Schweiss |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 3600 Nw Samaritan Dr, Corvallis, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063805786 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | DO192831 (Oregon) | Primary |
| 207P00000X | Emergency Medicine | 5101021574 (Michigan) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Regional Medical Center | Corvallis, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mary's Peak Emergency Physicians | 4688565559 | 5 |
News Archive
A review article published in the July/August 2005 Journal of Infusion Nursing examines the need for established treatment guidelines to support doctors and nurses in correctly dosing and administering intravenous immunoglobulin (IVIG) as replacement therapy in patients with primary immunodeficiency (PI) disorders, who do not produce adequate levels of antibodies essential in fighting infectious diseases.
An international group of researchers has shown that a regulatory protein involved in controlling how cancer spreads through the body also influences the fate of stem cells in the intestine of mice. The results, which are published in The EMBO Journal, show that the Snai1 protein plays an important role in deciding the fate of intestinal stem cells and the different functions that these cells can adopt.
Not enough communication takes place between drug companies and payers before Phase 3, according to a new study from Cutting Edge Information (http://www.cuttingedgeinfo.com/market-access/). The study finds that drug companies contact payers an average 2.4 times in all of Phase 2.
The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.
A JCU public health expert is off to Dili, Timor Leste (formerly East Timor) to help the World Health Organisation address three serious tropical diseases: lymphatic filariasis, intestinal worms and yaws.
› Verified 9 days ago
| Entity Name | Mary's Peak Emergency Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194733360 PECOS PAC ID: 4688565559 Enrollment ID: O20040322000521 |
News Archive
A review article published in the July/August 2005 Journal of Infusion Nursing examines the need for established treatment guidelines to support doctors and nurses in correctly dosing and administering intravenous immunoglobulin (IVIG) as replacement therapy in patients with primary immunodeficiency (PI) disorders, who do not produce adequate levels of antibodies essential in fighting infectious diseases.
An international group of researchers has shown that a regulatory protein involved in controlling how cancer spreads through the body also influences the fate of stem cells in the intestine of mice. The results, which are published in The EMBO Journal, show that the Snai1 protein plays an important role in deciding the fate of intestinal stem cells and the different functions that these cells can adopt.
Not enough communication takes place between drug companies and payers before Phase 3, according to a new study from Cutting Edge Information (http://www.cuttingedgeinfo.com/market-access/). The study finds that drug companies contact payers an average 2.4 times in all of Phase 2.
The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.
A JCU public health expert is off to Dili, Timor Leste (formerly East Timor) to help the World Health Organisation address three serious tropical diseases: lymphatic filariasis, intestinal worms and yaws.
› Verified 9 days ago
| Entity Name | Northwest Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235172370 PECOS PAC ID: 3476462334 Enrollment ID: O20050506000187 |
News Archive
A review article published in the July/August 2005 Journal of Infusion Nursing examines the need for established treatment guidelines to support doctors and nurses in correctly dosing and administering intravenous immunoglobulin (IVIG) as replacement therapy in patients with primary immunodeficiency (PI) disorders, who do not produce adequate levels of antibodies essential in fighting infectious diseases.
An international group of researchers has shown that a regulatory protein involved in controlling how cancer spreads through the body also influences the fate of stem cells in the intestine of mice. The results, which are published in The EMBO Journal, show that the Snai1 protein plays an important role in deciding the fate of intestinal stem cells and the different functions that these cells can adopt.
Not enough communication takes place between drug companies and payers before Phase 3, according to a new study from Cutting Edge Information (http://www.cuttingedgeinfo.com/market-access/). The study finds that drug companies contact payers an average 2.4 times in all of Phase 2.
The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.
A JCU public health expert is off to Dili, Timor Leste (formerly East Timor) to help the World Health Organisation address three serious tropical diseases: lymphatic filariasis, intestinal worms and yaws.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Schweiss, 3600 Nw Samaritan Dr, Corvallis, OR 97330-3737 Ph: () - | Robert Schweiss, 3600 Nw Samaritan Dr, Corvallis, OR 97330 Ph: (541) 768-5111 |
News Archive
A review article published in the July/August 2005 Journal of Infusion Nursing examines the need for established treatment guidelines to support doctors and nurses in correctly dosing and administering intravenous immunoglobulin (IVIG) as replacement therapy in patients with primary immunodeficiency (PI) disorders, who do not produce adequate levels of antibodies essential in fighting infectious diseases.
An international group of researchers has shown that a regulatory protein involved in controlling how cancer spreads through the body also influences the fate of stem cells in the intestine of mice. The results, which are published in The EMBO Journal, show that the Snai1 protein plays an important role in deciding the fate of intestinal stem cells and the different functions that these cells can adopt.
Not enough communication takes place between drug companies and payers before Phase 3, according to a new study from Cutting Edge Information (http://www.cuttingedgeinfo.com/market-access/). The study finds that drug companies contact payers an average 2.4 times in all of Phase 2.
The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.
A JCU public health expert is off to Dili, Timor Leste (formerly East Timor) to help the World Health Organisation address three serious tropical diseases: lymphatic filariasis, intestinal worms and yaws.
› Verified 9 days ago
Larry Dwayne Sebring, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 850 Sw 26th St, Corvallis, OR 97331 Phone: 541-737-9355 | |
Dr. Brent C. Wesenberg, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5234 Sw Philomath Blvd, Corvallis, OR 97333 Phone: 541-768-4970 | |
Dr. Benjamin Robert Oldson, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1282 | |
Brian Lee Delmonaco, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-5111 | |
Ronald U Vallejo, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 | |
Ethan B. Wilson, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-5021 |